IngenOx Therapeutics Receives New Patents for Compounds Inhibiting PRMT5

Oxford, UK – 6 July 2023  

Download this Press Release as a PDF

IngenOx Therapeutics, an Oxford-based clinical-stage biopharma company, has been granted patents for new compounds that inhibit PRMT5.

The new patents are for the composition of matter for AT101, the focus of IngenOx’s clinical PRMT5 inhibitor programme.

This is in addition to the granted patents by the US patent office (US11485731B2) granted in November 2022 by the US Patent and Trademark Office (USPTO), the Japan patent (JP7211982B2) granted in January 2023 by the Japan Patent Office (JPO), and the Singapore patent (SG11201908598) granted in May 2023 by the Intellectual Property Office of Singapore (IPOS).

The invention relates to compounds suitable for the inhibition of protein arginine methyltransferase (PRMT), in particular PRMT5. These compounds may be used as therapeutic agents for use in the treatment of/or prevention of proliferative diseases, such as cancer.

Nick La Thangue, CEO of IngenOx, and Professor of Cancer Biology at the University of Oxford commented:“We are delighted to receive these newly granted international patents. This highlights the innovation driving IngenOx’s growth and enables us to creatively differentiate ourselves in the PRMT5 field. Moving ahead, we will profile our lead PRMT5 inhibitor, AT101, in clinical studies and seek to achieve therapeutic benefits for patients suffering with clinically unmet cancers.”   NOTES:

About IngenOx Therapeutics

IngenOx Therapeutics is a bio-pharmaceutical company focused on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours. It is a spinout from the University of Oxford, and is located at the Oxford Science Park, UK. Its pipeline comprises early to late-stage products that work in different ways to activate the immune response against clinically unmet cancers, and which are generally poorly recognised by the immune system. An exciting proprietary platform technology focusses on precision cancer vaccines that act by targeting the immune response to cold cancers.

The company’s approach seeks to align the right drug with the right patient enabling a targeted precision medicine approach to cancer therapy. It has also built a proprietary platform around re-educating the body’s immune system to recognise and destroy tumours. The assets in its pipeline have displayed convincing clinical benefits to late-stage cancer patients through disease control, tumour shrinkage, reduced side effects, and extended survival times.

The company has secured institutional investment from a consortium of South Korean investors to advance its oncology assets. In 2019, additional investment was received from JW Pharmaceuticals, Oxford Science Enterprises, and a number of private investors. In 2020, the company incorporated SynOx Therapeutics, which was later spun out after securing investment from a group of European blue-chip VCs. It has signed global license partnerships with AstraZeneca and Roche.

Share This Post